ReviewJournal of translational autoimmunity2021

Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.

Buzon-Martín Luis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.